351 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1900)
- (-) Addiction (16)
- Allergy, Asthma, & Immunology (12)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (28)
- Blood Disorders (38)
- Bone & Muscle (10)
- Cancer (726)
- Child Development (4)
- COVID-19 (Coronavirus) (37)
- Critical Illness (1)
- Dental (2)
- Developmental Disorders (2)
- Diabetes (22)
- Ear, Nose and Throat (11)
- Endocrine & Metabolic Disease (13)
- Eye (8)
- Gastrointestinal and Digestive Diseases (22)
- Hair and Skin Disorders (2)
- Headaches (5)
- Healthy Volunteers (175)
- Heart Disease (128)
- Infectious Disease (48)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (48)
- Lung Disease (32)
- Meniere's Disease (1)
- Neurological Disorders (174)
- Nutrition (4)
- Obesity (9)
- Obstetrics & Gynecology (51)
- Pain Management (1)
- Pediatrics (104)
- Psychiatric Disorders (65)
- Rehabilitation (8)
- Stroke (7)
- Surgery (7)
- Transplant (51)
- Urology (4)
- Vascular Conditions (9)
Displaying 1 - 30 of 30
Condition: Blood Disorders / Amyloidosis
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
The purpose of this study is to see how safe and effective is the study drug, ABBV-383. ABBV-383 works by binding to a specific protein called B-cell maturation antigen, which is found on the surface of cells affected by amyloidosis. By engaging T-cells, a type of white blood cell, ABBV-383 helps activate the immune response to target and remove the…
Condition: Addiction / Nicotine
Investigator: Jonathan Overdevest, MD, PhD
Status: Currently Recruiting
The Columbia Otolaryngology Department is interested in understanding the intersection of vaping, smell, and taste and their impact on individuals' preferences for certain flavors. Participation will involve answering a series of questionnaires in addition to completing a formal evaluation of your smell and taste with standardized measurements. You can…
Condition: Ear, Nose and Throat / Loss of Smell
Investigator: Jonathan Overdevest, MD, PhD
Status: Currently Recruiting
Our research team at Columbia University is trying to understand the impact of COVID-19 on smell and taste (chemosensory) dysfunction among adult patients from the Greater New York City area. Current areas of study include: 1) Investigation of smell and taste recovery patterns among patients with COVID-19; 2) Studies on how recovery of smell and taste after…
Condition: Addiction / Opioids
Investigator: Dana Sacco, MD
Status: Currently Recruiting
The purpose of this research study is to evaluate how commonly drug overdoses in our community involve fentanyl and xylazine. We know that often drugs such as heroin, oxycontin, and even cocaine and methamphetamine, actually contain these additives, even though the person buying the drugs is not aware.
Condition: Blood Disorders / Amyloidosis
Investigator: Rajshekhar Chakraborty, MD
Status: Closed
The purpose of this study is to evaluate whether birtamimab plus standard of care will improve survival in subjects with Mayo Stage IV AL amyloidosis. Birtamimab has not yet been approved by the Food and Drug Administration (FDA). During the first phase of the study, the purpose of this study is to evaluate whether birtamimab plus standard of care will…
Condition: Addiction / Nicotine
Investigator: Ana Navas-Acien, MD, PHD, MPH
Status: Closed
The use of electronic cigarettes, also known as e-cigs or vaping, has increased among former smokers and young adults who have never smoked. Relatively little is known, however, about their health effects (whether they are adverse, have no effect, or are beneficial). The purpose of this research study is to evaluate (1) the association of e-cig use with…
Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of the study is to determine if the drug, CAEL-101 in combination with plasma cell treatment improves overall survival for patients who are diagnosed with stage 3b of AL amyloidosis. Patients who participate in this study will receive CAEL-101 as well as plasma cell treatment or Placebo as well as plasma cell treatment to compare the effects.
Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of the study is to determine if the drug, CAEL-101 in combination with plasma cell treatment improves overall survival for patients who are diagnosed with stage 3a of amyloid light chain (AL) amyloidosis. Patients who participate in this study will receive CAEL-101 as well as plasma cell treatment or Placebo as well as plasma cell treatment to…
Condition: Addiction / Marijuana
Investigator: Suzette Evans, PhD
Status: Closed
RESEARCH VOLUNTEERS: Healthy male and female (age 21-60) MARIJUANA SMOKERS needed to study effects of marijuana on brain activity and decision-making. The study involves 2-3 outpatient visits and a 5-day/5-night stay at the NYS Psychiatric Institute and includes Magnetic Resonance Imaging (MRI) scans. Compensation for time could be between $870-$1230 (…
Condition: Addiction / Nicotine
Investigator: Mariam Aly, PhD
Status: Closed
This is a four-session study in which we will be recruiting existing cigarette smokers to explore the competitive dynamics between memory encoding and memory retrieval. To participate, you will first go through a phone screening to determine eligibility and learn about the study. Then you will be asked to visit our facility at the Morningside Campus of…
Condition: Addiction / Opioids
Investigator: Sandra Comer, PhD
Status: Closed
Have an Opioid Use Disorder? We need your help for an inpatient clinical research study! Help the New York State Psychiatric Institute research better treatment options for those with opioid use disorder.You could earn up to $12,017.00.You must meet the following criteria: - Age 18 -59 years old- Have opioid use disorder- Be currently taking an oral daily…
Condition: Addiction / Cocaine
Investigator: Frances Levin, MD
Status: Closed
This study will test a computer-based behavioral intervention to decrease cocaine use. Those who fail to achieve cocaine abstinence after the first 4 weeks while receiving the behavioral treatment will continue the behavioral treatment and be randomly assigned to one of two groups (one group will receive Adderall-XR (MAS-ER) and the other group will receive…
Condition: Addiction
Investigator: Sandra Comer, PhD
Status: Closed
This 8-week inpatient study seeks to recruit healthy male and female patients who are currently using heroin or non-medically using opioid analgesics. Following screening, participants are admitted onto the inpatient unit where they complete testing sessions throughout the inpatient stay. Participants are compensated for each screening visit and for each…
Condition: Addiction / Opioids
Investigator: Jermaine Jones, PhD
Status: Closed
Healthy Black and Latino heroin users (male and female ages 25-55) are needed for a research study assessing the relationship between heroin use and cellular aging. The study involves a single visit to the New York State Psychiatric Institute, and consists of questionnaires and the collection of a blood sample for genetic testing. The visit will take about…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to evaluate the safety and effectiveness of an antibody drug (STI-6129) in patients with AL amyloidosis that has returned or has not responded to treatment (relapsed/refractory). The study drug (STI-6129) will be given in 3 injections through a needle, into a vein as an intravenous (IV), with 21 days between each injection.
Condition: Blood Disorders / Amyloidosis
Investigator: Thomas Brannagan, MD
Status: Closed
HELIOS-A is a global Phase 3 randomized, open-label study designed to evaluate the safety and efficacy of ALN-TTRSC02 in adult patients with hATTR amyloidosis experiencing neurologic symptoms brought on by the disease. The study will also evaluate any changes in quality of life experienced by study participants. ALN-TTRSC02 utilizes the mechanism of RNA…
Condition: Addiction / Opioids
Investigator: Sandra Comer, PhD
Status: Closed
Healthy heroin users (men and women, ages 21-59) are needed for an eight-week inpatient study investigating medication effects at the NY State Psychiatric Institute. Earn approximately $6,550 - $7,350.
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to test for any good and bad effects of the study drug called isatuximab. Isatuximab may or may not improve your AL amyloidosis, but it could also cause side effects. Isatuximab is not approved by the Food and Drug Administration (FDA). Isatuximab has been shown to have good effects in some patients with recurring multiple…
Condition: Addiction / Cocaine
Investigator: Frances Levin, MD
Status: Closed
The study is a two group outpatient study, one group receiving medications (Adderall-XR and topiramate) and one group receiving a placebo (inactive sugar pill). The study is looking at the safety and effectiveness of Adderall-XR (MAS-ER) and topiramate in the treatment of cocaine dependence. It is a 14-week trial that requires patients to attend visits 3…
Condition: Addiction / Opioids
Investigator: Frances Levin, MD
Status: Closed
This study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of a 5 day outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) for 8 weeks.
Condition: Blood Disorders / Amyloidosis
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to see if daratumumab when given with three other drugs cyclophosphamide, bortezomib (VELCADE) and dexamethasone is useful for treating patients with Amyloid light chain Amyloidosis (also known as AL Amyloidosis). The study will look at what happens (both good and bad) when daratumumab is given with these three drugs compared to…
Condition: Addiction / Opioids
Investigator: Mina Rizk, MD
Status: Closed
This research study uses MRI scans to compare the effect of two medications on suicidal thoughts and brain activity in people who have opioid use disorder. We hope to develop a better understanding of how well these two medications help depression and suicidal thoughts. You may qualify if you have opioid use disorder and suicidal thoughts. Participation…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to evaluate whether study drug NEOD001 will improve survival in subjects with AL amyloidosis and/or increase the interval of time that they can go without requiring hospitalization for problems with their hearts. This study will also evaluate whether NEOD001 improves the function of subjects' organs that have been affected…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to find out if MLN9708 plus dexamethasone improves against systemic light chain amyloidosis better than the physicians choice chemotherapy treatment. Physicians choice chemotherapy treatment is a treatment regimen that is commonly used to treat amyloidosis patients. The study will also determine if MLN9708 plus dexamethasone can…
Condition: Addiction / Alcohol
Investigator: Jennifer Elliott, PhD
Status: Closed
NOTE: YOU MUST HAVE HIV AND HAVE EVER HAD HEPATITIS C TO BE ELIGIBLE FOR THIS STUDY!! ............... For individuals who have both HIV and Hepatitis C virus (HCV), heavy drinking poses serious risks to their health. We do not yet know which interventions are effective at helping individuals with HIV and HCV drink less. The goal of the study is to compare…
Condition: Blood Disorders / Amyloidosis
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to evaluate the efficacy and safety of ION-682884 given for 24 months in patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) also known as Familial Amyloid Polyneuropathy (FAP), and determine if it can help people with mild or moderate polyneuropathy. To be in this study you must have FAP and be…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study for subjects that have been previously treated for systemic light chain (AL)amyloidosis (a disease in which abnormal protein deposits can damage organs and tissues in your body) and nowrequire further treatment. The main purpose of this study is to evaluate the safety and determine the maximum tolerated dose of aninvestigational new…
Condition: Addiction
Investigator: Jermaine Jones, PhD
Status: Closed
This study will assess the ability of the opioid antagonist, naltrexone, to block the effects of intranasal methamphetamine. This study is seeking healthy male and female users of psychostimulants like cocaine, methamphetamine between the ages of 21-50. For those who pass screening, the study consists of 4 outpatient testing sessions. Participants are…
Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The study is being done to see if the combination of bendamustine and dexamethasone will help people with amyloidosis that has returned after standard treatment. Bendamustine is currently approved by the Food and Drug Administration (FDA) for treatment of chronic lymphocytic leukemia (CLL) and is under clinical development in the United States for the…
Condition: Addiction / Marijuana
Investigator: Frances Levin, MD
Status: Closed
The study is an outpatient treatment study of the safety and benefit of extended-release mixed amphetamine salt (Adderall-XR) in the treatment of individuals with cannabis use disorder and Attention Deficit/Hyperactivity Disorder (ADHD). The study is a 13-week trial and requires participants to come twice per week. The primary objective of the study is to…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE